CAI (Caris) שולי רווח גולמי

CAI (Caris Corp) - סמל מסחרי של החברה

The gross margin trend helps identify rising costs in a timely manner, with 69.10 recorded as the baseline value. Caris Life Sciences (CAI) maintains premium pricing due to its highly complex molecular cancer analysis. A steady cash flow from diagnostics covers innovation costs. Revenues are diversified through partnerships with oncologists and biopharma behemoths, which minimizes market risks.

CAI (Caris Life Sciences) היסטוריית שולי רווח גולמי מ-19.06.2025 עד 20.11.2026

פילוחי מדדים מקיפים ואנליטיקה עבור Caris Life Sciences, Inc. (CAI)

ניתוח בסיסי של החברה:Caris Life Sciences, CAI
מוצר סדרתי של Caris Corp

Gross margin measures production efficiency by capturing the portion of revenue remaining after direct costs. A stable indicator level confirms the business's pricing power, while a decline signals rising costs. By analyzing the current gross margin, an investor assesses the company's ability to scale profits. For Caris Life Sciences, Inc. (CAI), this reflects the cost of genomic data generation and the efficiency of AI diagnostics within the personalized medicine segment.